CaffeinevsOxiracetam

Caffeine is a non-selective adenosine receptor antagonist with highest affinity for A1 and A2A subtypes. Adenosine accumulates during wakefulness and promotes sleepiness by binding to A1 receptors (inhibiting adenylyl cyclase and reducing neuronal excitability) and A2A receptors (modulating dopamine D2 receptor signaling in striatum). Caffeine competitively blocks these receptors, preventing the drowsiness signal. This disinhibition indirectly increases dopamine, norepinephrine, and acetylcholine neurotransmission via downstream pathways. Caffeine also inhibits phosphodiesterase (PDE) enzymes—particularly PDE4 in the brain—reducing cAMP degradation. Elevated intracellular cAMP amplifies catecholamine signaling through PKA-mediated phosphorylation of CREB and other transcription factors, enhancing alertness and cognitive performance.

Oxiracetam enhances glutamatergic neurotransmission through positive allosteric modulation of AMPA receptors, increasing the amplitude and duration of excitatory postsynaptic potentials. It increases the release of excitatory neurotransmitters glutamate and D-aspartic acid from hippocampal presynaptic terminals, acting as a glutamate analog. Oxiracetam stimulates protein kinase C (PKC) isoforms, particularly PKC-α and PKC-γ, which phosphorylate substrates involved in memory consolidation, long-term potentiation (LTP), and synaptic plasticity. PKC activation enhances NMDA receptor function and AMPA receptor trafficking to the synapse. Its mild stimulatory effect derives from cholinergic system enhancement via increased acetylcholine release and nicotinic α7 receptor potentiation in the cortex.